Ratings by Oppenheimer (Mazahir Alimohamed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/12/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Outperform (N/A) |
19.37 (32.11) |
65.77% | Details | |
| 7/9/2026 | Edgewise Therapeutics | EWTX | New Coverage | Outperform (N/A) |
46.30 (42.25) |
-8.75% | Details | |
| 6/22/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (Outperform) |
7.56 (8.82) |
16.67% | Details | |
| 6/17/2026 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
28.21 (25.30) |
-10.32% | Details | |
| 6/10/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Outperform (N/A) |
1.67 (2.38) |
42.51% | Details | |
| 5/20/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Outperform (N/A) |
60.97 (74.05) |
21.45% | Details | |
| 4/24/2026 | Inflarx NV | IFRX | New Coverage | Outperform (N/A) |
1.56 (2.16) |
38.46% | Details | |
| 4/24/2026 | Savara | SVRA | New Coverage | Outperform (N/A) |
4.94 (5.35) |
8.3% | Details | |
| 4/24/2026 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
4.07 (5.24) |
28.75% | Details |
